[Reduction of cardiovascular morbidity/mortality in arteriopathies treated ith PGE1 alpha-cyclodextrin].

Abstract

BACKGROUND:

Cardiovascular morbidity and mortality were evaluated in two groups of vascular patients (one treated with PGE1 alpha-ciclodestrina according to the short term protocol and one reference group) with a follow up of at least 24 month.

METHODS:

The former group included patients who had been treated with at least four PGE1 alpha-ciclodestrina, short-term treatment cycles per year while the latter was a historical reference group managed without prostaglandins. The two groups were comparable for sex and age distribution.

RESULTS:

In the PGE1 alpha-ciclodestrina group 142 patients (mean age 64 +/- 17; M:F = 84:58) had been treated (47 for intermittent claudication and 95 for critical ischemia: 43 for rest pain, and 52 for localised gangrene). The historical reference group included 157 patients (mean age 65 +/- 18: M:F = 91:66); 53 with intermittent claudication and 104 with critical ischemia (49 rest pain, 55 gangrene). In claudicants yearly cardiovascular morbidity was reduced from the 15% observed in the reference group to 10% in patients treated with PGE1 alpha-ciclodestrina. Yearly mortality decreased from 11% in the reference group to 6% in the treated group. In rest pain patients morbidity decreased from 24% in the reference group to 19% in the treated group. Mortality also decreased (from 16% to 11%). In patients with gangrene the difference in morbidity between the reference group (35%) and the PGE1 alpha-ciclodestrina group (27%) was even more evident (P < 0.025). In this group the mortality per year was reduced from 26% in the reference group to 17% in the PGE1 alpha-ciclodestrina treated group.

CONCLUSION:

It appears that cyclic treatment with PGE1 alpha-ciclodestrina produces not only an improvement in signs and symptoms related to vascular disease but also an important decrease in cardiovascular morbidity and mortality which has not been previously reported.

• Authors: G Belcaro, M Bucci, M R Cesarone, L Incandela, M T De Sanctis
• Journal: Minerva cardioangiologica (Minerva Cardioangiol) Vol. 46 Issue 10 Suppl 1 Pg. 51-4 (Oct 1998) ISSN: 0026-4725 [Print] Italy
• Vernacular Title: Riduzione di morbidità/mortalità cardiovascolare in arteriopatici in trattamento con PGE1 alpha-ciclodestrina.
• PMID: 10658445 (Publication Type: Clinical Trial, Clinical Trial, Phase II, English Abstract, Journal Article, Randomized Controlled Trial)

Chemical References

• Cyclodextrins
• Alprostadil

Topics

• Age Distribution
• Aged
• Alprostadil (pharmacology, therapeutic use)
• Cardiovascular Diseases (drug therapy, epidemiology, mortality)
• Cyclodextrins (pharmacology, therapeutic use)
• Female
• Follow-Up Studies
• Gangrene (drug therapy)
• Humans
• Intermittent Claudication (drug therapy)
• Ischemia (drug therapy)
• Male
• Middle Aged
• Sex Ratio